Eupraxia Pharmaceuticals Inc (EPRX)
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker EPRX. The company is developing treatments for areas with significant unmet medical need and uses its proprietary Diffusphere technology to improve drug delivery. Its pipeline includes EP-104IAR, which is in a Phase III trial for knee osteoarthritis; EP-104GI, which is in Phase II testing for eosinophilic esophagitis; and EP-104, which remains in preclinical development for gastrointestinal tract conditions, including eosinophilic esophagitis. Eupraxia Pharmaceuticals was incorporated in 2011, adopted its current name in 2012, and is headquartered in Victoria, Canada.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EPRX
|
$5.04
|
-22.4% Downside
|
Overvalued
|
$16.28
|
150.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-9.0x
|
3.9x
|
—
|
410.3 M
|
317.2 M
|
0.5%
|
78.5%
|
18.7
|
—
|
71.2%
|
